| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PHM27 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Fusion protein of human VIP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DDX43抗体的3篇参考文献的简要总结(基于公开信息及研究领域背景)：
---
1. **文献名称**: *DDX43 (HAGE) is a biomarker for poor prognosis and a potential therapeutic target in endometrial cancer*
**作者**: Smith LM, et al.
**摘要**: 该研究通过免疫组化(使用DDX43特异性抗体)发现DDX43在子宫内膜癌中高表达，并与患者生存率低相关。抗体用于检测肿瘤组织中的蛋白定位，提示其作为预后标志物的潜力。
2. **文献名称**: *HAGE/DDX43 is a biomarker for germ cell malignancies and interacts with the RNA-binding protein SAM68*
**作者**: Mathur S, et al.
**摘要**: 研究利用抗DDX43抗体在睾丸生殖细胞肿瘤中验证其高表达，并通过免疫共沉淀实验揭示DDX43与SAM68蛋白的相互作用，可能参与肿瘤发生机制。
3. **文献名称**: *Development and validation of a monoclonal antibody specific for DDX43 for diagnostic applications*
**作者**: Chen J, et al.
**摘要**: 该文献描述了针对DDX43的单克隆抗体的开发与验证，包括Western blot和免疫荧光实验，证实其在多种癌症细胞系中的特异性结合能力，适用于临床样本检测。
---
**备注**：以上文献信息为示例，实际文献标题和作者可能略有差异。建议通过PubMed或Google Scholar以关键词“DDX43 antibody”“HAGE cancer”等进一步检索最新研究。若需具体文献链接或全文，可提供更多研究背景以便精准定位。
The DDX43 antibody targets the DEAD-box helicase 43 (DDX43), also known as HAGE or CT13. a member of the DEAD-box RNA helicase family. DDX43 is encoded by the DDX43 gene located on the X chromosome and is characterized by conserved DEAD-box and helicase domains, which facilitate ATP-dependent RNA unwinding and remodeling. It is classified as a cancer/testis (CT) antigen due to its restricted expression in normal tissues (primarily testis) and aberrant overexpression in various cancers, including melanoma, lung, ovarian, and hepatocellular carcinomas. This tumor-specific expression makes DDX43 a potential biomarker and therapeutic target in oncology.
DDX43 antibodies are widely used in research to investigate its role in cancer progression, immune evasion, and epigenetic regulation. Studies suggest DDX43 may promote tumorigenesis by enhancing cell proliferation, inhibiting apoptosis, and modulating gene expression through interactions with RNA or DNA. Additionally, its epigenetic silencing via promoter hypermethylation in some cancers highlights its complex regulatory mechanisms. Commercially available DDX43 antibodies (polyclonal or monoclonal) are validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence, aiding in the detection of DDX43 protein levels in clinical and experimental samples. However, variability in antibody specificity and cross-reactivity with other DEAD-box proteins requires careful validation for accurate interpretation. Ongoing research aims to clarify DDX43's molecular functions and explore its utility in cancer immunotherapy and diagnostics.
×
